Tickerover
Healthcare

TECH Stock Analysis

Bio-Techne Corporation · current price $72.35 (-0.17% today)

Setup looks favourable on the available data. Caveat: trades 2.2% above analyst mean target. Stock is trading above the analyst mean target ($71) — limited consensus headroom.
★★★★
Quality
📊

The six-pillar scorecard

Momentum
71
Trending up strong
price trend
Growth
25
Barely growing
sales & profit growth
Quality
99
High quality
profitability & balance sheet
Valuation
65
Fairly priced
is the price fair?
Sentiment
37
Mixed views
analyst & crowd mood
Risk
69
Moderate risk
volatility & drawdown

Each pillar is scored 0-100 inside the stock’s own peer group, so a chipmaker is measured against chipmakers. These are quality descriptors, not buy or sell signals.

📉

The picture

What drove the scoreThe seven components contributing most, each read out of 100.
Relative strengthRelative strength: 100100Trend strengthTrend strength: 100100RSI zoneRSI zone: 85851-month momentum1-month momentum: 5050Breakout proximityBreakout proximity: 7676GrowthGrowth: 4040FundamentalsFundamentals: 7171
Margin profileWhat survives each step down the income statement.
GrossGross: 66.2%66.2%OperatingOperating: 27.9%27.9%NetNet: 15.0%15.0%Free cash flowFree cash flow: 22.2%22.2%
EPS surpriseReported EPS against estimate, last four quarters.
2026-03: -82.0% vs estimate-82%2026-032025-12: -7.7% vs estimate-8%2025-122025-09: -36.0% vs estimate-36%2025-092025-06: +5.8% vs estimate+6%2025-06
👁

Hype Check

Reading TECH’s price and volume history…

The audit — what has to hold for this thesis

Checking the areas that decide this thesis…

AI-generated from the company’s own filings and recent coverage, and it can be incomplete or wrong. A PASS is a reading of the cited evidence, not a verified fact and not a reason to buy. Follow each citation to the source.

🛡

Dilution Check

Reading TECH’s filings…

📣

Latest earnings

LAST EARNINGS Bio-Techne Corporation (TECH)

Latest earnings

EPS
$0.53 vs $0.50 est · +5.8% vs estimate BEAT
Revenue
$311.4M · -1.8% YoY
Stock reaction (1M)
+0.6%
Beat streak
1 of last 4 quarters
💰

Valuation

P/E
62.4×
Forward P/E
31.2×
PEG
0.97
Price / Sales
9.3×
Price / Book
5.4×
EV / EBITDA
34.0×
Analyst target
$70.73
Target range
$50.00 – $73.00
Implied upside
-2.2%
🩺

Financial health

Gross margin
66.2%
Operating margin
27.9%
Net margin
15.0%
FCF margin
22.2%
Return on equity
9.0%
Debt / equity
0.14
Revenue growth YoY
+1.3%
📈

Technicals

$43.2052-week range$72.62
RSI (14)
66
50-day MA
$70.60
200-day MA
$60.69
ATR (14)
0.24
Beta
1.28
1-month return
+0.6%
🗓️

Earnings

QuarterEPSEst.SurpriseResult
2025-06-30$0.53$0.50+5.8%Beat
2025-09-30$0.42$0.42-0.4%Miss
2025-12-31$0.24$0.26-7.7%Miss
2026-03-31$0.53$0.53-0.8%Miss
Beat 1 of the last 4 quarters.
🏛️

Ownership & risk

Short % of float
0.05%
Dividend yield
0.44%
Beta
1.28
📰

Latest news on TECH

🔗

Similar stocks in Healthcare

Frequently asked

What is TECH's Quant Score?

Bio-Techne Corporation (TECH) currently has a TickerMover Quant Score of 65/100, rated ★★★★ Quality. The Quant Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.

Is Bio-Techne Corporation (TECH) a buy?

TickerMover does not give buy or sell recommendations. TECH scores 65/100 (★★★★ Quality) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.

How often is TECH's score updated?

TECH's Quant Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.

Get the full live dashboard

Real-time scoring, conflict detection, Reverse DCF and peer comparison — free while in beta.

Open the dashboard for TECH →